News
Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...
MetaVia Inc. ( Nasdaq: MTVA) announced that a late-breaking abstract highlighting Phase 2a data from its DA-1241 program in presumed metabolic dysfunction-associated steatohepatitis (MASH) has been ...
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback